Economic analysis of vancomycin-resistant enterococci at a Canadian hospital: Assessing attributable cost and length of stay

Journal of Hospital Infection

Volumn 85, Issue 1, 2013, Pages 54-59

  Lloyd Smith, P ^a,b   Younger, J ^b   Lloyd Smith, E ^c   Green, H ^c   Leung, V ^c,d   Romney, M G ^c,d  

^a UNIVERSITY OF ALBERTA   (Canada)

^b Mayne Economics   (Canada)

^c ST PAUL S HOSPITAL   (Canada)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Economics; Hospital; Infection control; Vancomycin resistant enterococcus (VRE)

Indexed keywords

ADULT; ARTICLE; BACTERIAL COLONIZATION; BACTERIAL INFECTION; BLOOD; CANADA; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DIALYSATE; DISEASE SURVEILLANCE; ECONOMIC EVALUATION; FECES; FEMALE; HOSPITAL CARE; HOSPITAL COST; HOSPITALIZATION COST; HUMAN; ICD-10; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; RECTUM; SKIN; SPUTUM; URINE; VANCOMYCIN RESISTANT ENTEROCOCCUS;

EID: 84881661761     PISSN: 01956701     EISSN: 15322939     Source Type: Journal    
DOI: 10.1016/j.jhin.2013.06.016     Document Type: Article

References (21)

1. Stosor V., Peterson L.R., Postelnick M., Noskin G.A. Enterococcus faecium bacteremia: does vancomycin resistance make a difference?. Arch Intern Med 1998, 158:522-527.
2. Bhorade S.M., Christenson J., Pohlman A.S., Arnow P.M., Hall J.B. The incidence of and clinical variables associated with vancomycin-resistant enterococcal colonization in mechanically ventilated patients. Chest 1999, 115:1085-1091.
3. Roughmann M., Bradham D., South B., Clark C.C., Noga E.M., Sexton D.J. The clinical and economic impact of antimicrobial drug resistance on nosocomial bloodstream infections. Infect Control Hosp Epidemiol 2000, 21:97.
4. Webb M., Riley L.W., Roberts R.B. Cost of hospitalization for and risk factors associated with vancomycin-resistant Enterococcus faecium infection and colonization. Clin Infect Dis 2001, 33:445-452.
5. Pelz R.K., Lipsett P.A., Swoboda S.M., et al. Vancomycin-sensitive and vancomycin-resistant enterococcal infections in the ICU: attributable costs and outcomes. Intensive Care Med 2002, 28:692-697.
6. Carmelli Y., Eliopoulos G., Mozafarri E., Samore M. Health and economic outcomes of vancomycin-resistant Enterococci. Arch Intern Med 2002, 162:2223-2228.
7. Song X., Srinivasan A., Plaut D., Perl T.M. Effect of nosocomial vancomycin-resistant Enterococcal bacteremia on mortality, length of stay, and costs. Infect Cont Hosp Epidemiol 2003, 24:251-256.
8. Puzniak L.A., Gillespie K.N., Leet T., Kollef M., Mundy L.M. Acost-benefit analysis of gown use in controlling vancomycin-resistant Enterococcus transmission: is it worth the price?. Infect Control Hosp Epidemiol 2004, 25:418-424.
9. Butler A.M., Olsen M.A., Merz L.R., et al. Attributable costs of enterococcal bloodstream infections in a nonsurgical hospital cohort. Infect Control Hosp Epidemiol 2010, 31:28-35.
10. Nguyen G.C., Leung W., Weizman A.V. Increased risk of vancomycin-resistant enterococcus (VRE) infection among patients hospitalized for inflammatory bowel disease in the United States. Inflam Bowel Dis 2010, 17:1338-1342.
11. Roberts R.R., Scott R.D., Hota B., et al. Costs attributable to healthcare-acquired infection in hospitalized adults and a comparison of economic methods. Med Care 2010, 48:1026-1035.
12. Zoutman D.E., Ford B.D., Bryce E., et al. Canadian Hospital Epidemiology Committee; Canadian Noscomial Infection Surveillance Program; Health Canada. The state of infection surveillance and control in Canadian acute care hospitals. Am J Infect Control 2003, 31:266-272.
13. Graves N., Weinhold D., Tong E., et al. Effect of healthcare-acquired infection on length of hospital stay and cost. Infect Control Hosp Epidemiol 2007, 28:280-292.
14. Moran J.L., Solomon P.J., Peisach A.R., Martin J. New models for old questions: generalized linear models for cost prediction. JEval Clin Pract 2007, 13:381-389.
15. Blough D.K., Ramsey S.D. Using generalized linear models to assess medical care costs. Health Serv Outcomes Res Methodol 2000, 1:185-202.
16. Roberts R.R., Scott R.D., Cordell R., et al. The use of economic modeling to determine the hospital costs associated with nosocomial infections. Clin Infect Dis 2003, 36:1424-1432.
17. Kennedy P.E. Estimation with correctly interpreted dummy variables in semilogarithmic equations. Am Econ Rev 1981, 71:801.
18. Stone P.W., Braccia D., Larson E. Systematic review of economic analyses of health care-associated infections. Am J Infect Control 2005, 33:501-509.
19. Graves N., Weinhold D. Complexity and the attribution of cost to hospital acquired infection. The economics of infectious disease 2006, 103-127. Oxford University Press, New York. J.A. Roberts (Ed.).
20. Graves N., Weinhold D., Roberts J.A.R. Correcting for bias when estimating the cost of hospital acquired infection: an analysis of lower respiratory tract infections in non-surgical patients. Health Econ 2005, 14:755-761.
21. Roberts R.R., Hota B., Ahmad I., et al. Hospital and societal costs of antimicrobial-resistant infections in a Chicago teaching hospital: implications for antibiotic stewardship. Clin Infect Dis 2009, 49:1175-1184.